News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK), Shionogi & Co., Ltd. Say HIV Drug Beats Gilead Sciences, Inc. (GILD) Atripla in Test



7/11/2012 6:44:43 AM

An experimental treatment for HIV developed by GlaxoSmithKline Plc (GSK), Pfizer Inc. (PFE) (PFE) and Shionogi & Co. (4507) reduced the virus in more people than Gilead Sciences Inc. (GILD) (GILD)’s Atripla, suggesting it may supplant the world’s best-selling AIDS medicine as the preferred front-line therapy. After 48 weeks of treatment, 88 percent of patients receiving a combination of dolutegravir and two other drugs in a study had undetectable levels of virus in their blood, compared with 81 percent of those getting Atripla, London-based Glaxo and Shionogi of Osaka, Japan, said in a joint statement today. The difference was primarily the result of more patients on Atripla dropping out because of side effects, they said.

Read at BusinessWeek
Read at Reuters
Read at Share Cast
Read at News Release


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES